Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Neuropsychopharmacology ; 42(9): 1841-1849, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28393895

RESUMEN

Methadone and buprenorphine are currently the most common pharmacological treatments for opioid dependence. Interestingly, the clinical response to these drugs appears to be sex specific. That is, females exhibit superior therapeutic efficacy, defined as extended periods of abstinence and longer time to relapse, compared with males. However, the underlying metabolic effects of opioid withdrawal and replacement have not been examined. Therefore, using 18FDG and microPET, we measured differences in regional brain glucose metabolism in males and females following morphine withdrawal and subsequent methadone or buprenorphine replacement. In both males and females, spontaneous opioid withdrawal altered glucose metabolism in regions associated with reward and drug dependence. Specifically, metabolic increases in the thalamus, as well as metabolic decreases in insular cortex and the periaqueductal gray, were noted. However, compared with males, females exhibited increased metabolism in the preoptic area, primary motor cortex, and the amygdala, and decreased metabolism in the caudate/putamen and medial geniculate nucleus. Methadone and buprenorphine initially abolished these changes uniformly, but subsequently produced their own regional metabolic alterations that varied by treatment and sex. Compared with sex-matched control animals undergoing spontaneous opioid withdrawal, male animals treated with methadone exhibited increased caudate/putamen metabolism, whereas buprenorphine produced increased ventral striatum and motor cortex metabolism in females, and increased ventral striatum and somatosensory cortex metabolism in males. Notably, when treatment effects were compared between sexes, methadone-treated females showed increased cingulate cortex metabolism, whereas buprenorphine-treated females showed decreased metabolism in cingulate cortex and increased metabolism in the globus pallidus. Perhaps the initial similarities in males and females underlie early therapeutic efficacy, whereas these posttreatment sex differences contribute to clinical treatment failure more commonly experienced by the former.


Asunto(s)
Encéfalo/metabolismo , Glucosa/metabolismo , Dependencia de Morfina/tratamiento farmacológico , Dependencia de Morfina/metabolismo , Caracteres Sexuales , Analgésicos Opioides/farmacología , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Mapeo Encefálico , Buprenorfina/farmacología , Estudios Transversales , Modelos Animales de Enfermedad , Femenino , Fluorodesoxiglucosa F18 , Estudios Longitudinales , Masculino , Metadona/farmacología , Morfina/farmacología , Dependencia de Morfina/diagnóstico por imagen , Tomografía de Emisión de Positrones , Radiofármacos , Ratas Sprague-Dawley , Resultado del Tratamiento
2.
J Addict Res Ther ; 7(4)2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-28078167

RESUMEN

The rate of Neonatal Abstinence Syndrome (NAS) has drastically increased over the past decade. The average hospital expense per NAS patient has tripled, while the number of babies born to opioid-dependent mothers has increased to 5 in 1000 births. Current treatment options are limited to opioid replacement and tapering. Consequently, we examined the efficacy of prenatal, low-dose and short-term vigabatrin (γ-vinyl GABA, GVG) exposure for attenuating these symptoms as well as the metabolic changes observed in the brains of these animals upon reaching adolescence. Pregnant Sprague-Dawley rats were treated in one of four ways: 1) saline; 2) morphine alone; 3) morphine+GVG at 25 mg/kg; 4) morphine+GVG at 50 mg/kg. Morphine was administered throughout gestation, while GVG administration occurred only during the last 5 days of gestation. On post-natal day 1, naloxone-induced withdrawal behaviours were recorded in order to obtain a gross behaviour score. Approximately 28 days following birth, 18FDG microPET scans were obtained on these same animals (Groups 1, 2, and 4). Morphine-treated neonates demonstrated significantly higher withdrawal scores than saline controls. However, GVG at 50 but not 25 mg/kg/day significantly attenuated them. Upon reaching adolescence, morphine treated animals showed regionally specific changes in 18FDG uptake. Again, prenatal GVG exposure blocked them. These data demonstrate that low-dose, short-term prenatal GVG administration blocks naloxone-induced withdrawal in neonates. Taken together, these preliminary findings suggest that GVG may provide an alternative and long-lasting pharmacologic approach for the management of neonatal and adolescent symptoms associated with NAS.

3.
J Med Chem ; 55(1): 357-66, 2012 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-22128851

RESUMEN

Vigabatrin, a GABA aminotransferase (GABA-AT) inactivator, is used to treat infantile spasms and refractory complex partial seizures and is in clinical trials to treat addiction. We evaluated a novel GABA-AT inactivator (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115, compound 1) and observed that it does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. By use of in vivo microdialysis techniques in freely moving rats and microPET imaging techniques, 1 produced similar inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens at (1)/(300) to (1)/(600) the dose of vigabatrin. It also blocks expression of cocaine-induced conditioned place preference at a dose (1)/(300) that of vigabatrin. Electroretinographic (ERG) responses in rats treated with 1, at doses 20-40 times higher than those needed to treat addiction in rats, exhibited reductions in ERG responses, which were less than the reductions observed in rats treated with vigabatrin at the same dose needed to treat addiction in rats. In conclusion, 1 can be administered at significantly lower doses than vigabatrin, which suggests a potential new treatment for addiction with a significantly reduced risk of visual field defects.


Asunto(s)
4-Aminobutirato Transaminasa/metabolismo , Ácidos Carboxílicos/síntesis química , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Ciclopentanos/síntesis química , Animales , Disponibilidad Biológica , Ácidos Carboxílicos/farmacología , Ácidos Carboxílicos/toxicidad , Trastornos Relacionados con Cocaína/metabolismo , Trastornos Relacionados con Cocaína/psicología , Ciclopentanos/farmacología , Ciclopentanos/toxicidad , Perros , Dopamina/metabolismo , Electrorretinografía , Femenino , Proteínas Transportadoras de GABA en la Membrana Plasmática/fisiología , Inhibidores de Recaptación de GABA/síntesis química , Inhibidores de Recaptación de GABA/farmacología , Inhibidores de Recaptación de GABA/toxicidad , Humanos , Masculino , Ratones , Microdiálisis , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Oocitos/efectos de los fármacos , Oocitos/fisiología , Tomografía de Emisión de Positrones , Prolina/análogos & derivados , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Receptores de GABA/metabolismo , Retina/efectos de los fármacos , Retina/fisiología , Estereoisomerismo , Distribución Tisular , Vigabatrin/farmacología , Xenopus laevis
4.
Am J Psychiatry ; 166(11): 1269-77, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19651710

RESUMEN

OBJECTIVE: Cocaine dependence is associated with severe medical, psychiatric, and social morbidity, but no pharmacotherapy is approved for its treatment in the United States. The atypical antiepileptic vigabatrin (gamma-vinyl gamma-aminobutyric acid [GABA]) has shown promise in animal studies and open-label trials. The purpose of the present study was to assess the efficacy of vigabatrin for short-term cocaine abstinence in cocaine-dependent individuals. METHOD: Participants were treatment seeking parolees who were actively using cocaine and had a history of cocaine dependence. Subjects were randomly assigned to a fixed titration of vigabatrin (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment. Cocaine use was determined by directly observed urine toxicology testing twice weekly. The primary endpoint was full abstinence for the last 3 weeks of the trial. RESULTS: Full end-of-trial abstinence was achieved in 14 vigabatrin-treated subjects (28.0%) versus four subjects in the placebo arm (7.5%). Twelve subjects in the vigabatrin group and two subjects in the placebo group maintained abstinence through the follow-up period. The retention rate was 62.0% in the vigabatrin arm versus 41.5% in the placebo arm. Among subjects who reported prestudy alcohol use, vigabatrin, relative to placebo, was associated with superior self-reported full end-of-trial abstinence from alcohol (43.5% versus 6.3%). There were no differences between the two groups in drug craving, depressed mood, anxiety, or Clinical Global Impression scores, and no group differences in adverse effects emerged. CONCLUSIONS: This first randomized, double-blind, placebo-controlled trial supports the safety and efficacy of short-term vigabatrin treatment of cocaine dependence.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Americanos Mexicanos/estadística & datos numéricos , Vigabatrin/uso terapéutico , Adulto , Alcoholismo/rehabilitación , Alcoholismo/terapia , Trastornos Relacionados con Cocaína/rehabilitación , Terapia Combinada , Método Doble Ciego , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Masculino , Americanos Mexicanos/legislación & jurisprudencia , Americanos Mexicanos/psicología , Placebos , Índice de Severidad de la Enfermedad , Detección de Abuso de Sustancias/estadística & datos numéricos , Templanza/estadística & datos numéricos , Resultado del Tratamiento , Población Urbana
5.
J Neurosci ; 29(19): 6176-85, 2009 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-19439595

RESUMEN

Positron emission tomography studies in drug-addicted patients have shown that exposure to drug-related cues increases striatal dopamine, which displaces binding of the D(2) ligand, [(11)C]-raclopride. However, it is not known if animals will also show cue-induced displacement of [(11)C]-raclopride binding. In this study, we use [(11)C]-raclopride imaging in awake rodents to capture cue-induced changes in dopamine release associated with the conditioned place preference model of drug craving. Ten animals were conditioned to receive cocaine in a contextually distinct environment from where they received saline. Following conditioning, each animal was tested for preference and then received two separate [(11)C]-raclopride scans. For each scan, animals were confined to the cocaine and/or the saline-paired environment for the first 25 min of uptake, after which they were anesthetized and scanned. [(11)C]-raclopride uptake in the saline-paired environment served as a within-animal control for uptake in the cocaine-paired environment. Cocaine produced a significant place preference (p = 0.004) and exposure to the cocaine-paired environment decreased [(11)C]-raclopride binding relative to the saline-paired environment in both the dorsal (20%; p < 0.002) and ventral striatum (22%; p < 0.05). The change in [(11)C]-raclopride binding correlated with preference in the ventral striatum (R(2) = -0.87; p = 0.003). In this region, animals who showed little or no preference exhibited little or no change in [(11)C]-raclopride binding in the cocaine-paired environment. This noninvasive procedure of monitoring neurochemical events in freely moving, behaving animals advances preclinical molecular imaging by interrogating the degree to which animal models reflect the human condition on multiple dimensions, both biological and behavioral.


Asunto(s)
Trastornos Relacionados con Cocaína/fisiopatología , Cocaína , Cuerpo Estriado/fisiopatología , Señales (Psicología) , Dopamina/metabolismo , Animales , Radioisótopos de Carbono , Trastornos Relacionados con Cocaína/diagnóstico por imagen , Condicionamiento Psicológico , Cuerpo Estriado/diagnóstico por imagen , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Masculino , Actividad Motora , Tomografía de Emisión de Positrones , Racloprida/metabolismo , Racloprida/farmacología , Ratas , Ratas Sprague-Dawley , Percepción Espacial/efectos de los fármacos
6.
Synapse ; 63(2): 87-94, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19016239

RESUMEN

Preventing relapse poses a significant challenge to the successful management of methamphetamine (METH) dependence. Although no effective medication currently exists for its treatment, racemic gamma vinyl-GABA (R,S-GVG, vigabatrin) shows enormous potential as it blocks both the neurochemical and behavioral effects of a variety of drugs, including METH, heroin, morphine, ethanol, nicotine, and cocaine. Using the reinstatement of a conditioned place preference (CPP) as an animal model of relapse, the present study specifically investigated the ability of an acute dose of R,S-GVG to block METH-triggered reinstatement of a METH-induced CPP. Animals acquired a METH CPP following a 20-day-period of conditioning, in which they received 10 pairings of alternating METH and saline injections. During conditioning, rats were assigned to one of four METH dosage groups: 1.0, 2.5, 5.0, or 10.0 mg/kg (i.p., n = 8/group). Animals in all dosage groups demonstrated a robust and consistent CPP. This CPP was subsequently extinguished in each dosage group with repeated saline administration. Upon extinction, all groups reinstated following an acute METH challenge. On the following day, an acute dose of R,S-GVG (300 mg/kg, i.p.) was administered 2.5 h prior to an identical METH challenge. R,S-GVG blocked METH-triggered reinstatement in all four groups. Given that drug re-exposure may potentiate relapse to drug-seeking behavior, the ability of R,S-GVG to block METH-triggered reinstatement offers further support for its use in the successful management of METH dependence.


Asunto(s)
Trastornos Relacionados con Anfetaminas/prevención & control , Estimulantes del Sistema Nervioso Central/efectos adversos , GABAérgicos/farmacología , Metanfetamina/efectos adversos , Vigabatrin/farmacología , Animales , Condicionamiento Clásico/efectos de los fármacos , Extinción Psicológica/efectos de los fármacos , Isomerismo , Masculino , Ratas , Ratas Sprague-Dawley , Recurrencia
7.
Synapse ; 62(11): 870-2, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18720383

RESUMEN

Given the growing obesity epidemic, pressure to develop an effective pharmacologic treatment is mounting. Following the completion of a randomized, double-blind, placebo controlled trial as well as two small open label trials, gamma vinyl-GABA (GVG) has been shown to be safe and effective for treating cocaine and/or methamphetamine dependence. In an extension of these findings, the present study examined whether GVG could produce weight loss in adolescent as well as genetically obese animals. Specifically, adolescent Sprague Dawley and adolescent and adult Zucker fatty rats received GVG at various doses (75-300 mg/kg, i.p., racemic) for treatment periods lasting no longer than 14 consecutive days. GVG produced significant weight loss in a dose dependent fashion in all groups. These effects were marked, as average decreases of 12-20% of original body weight were observed. These findings suggest that GVG may be useful as a treatment for obesity. Further, that these results occurred in genetically obese animals offers the possibility that GVG may even help manage severe obesity resulting from binge-eating, a disorder involving food consumption in a pattern similar to the compulsive drug-seeking behavior observed in cocaine and methamphetamine dependent subjects.


Asunto(s)
Vigabatrin/administración & dosificación , Vigabatrin/farmacología , Pérdida de Peso/efectos de los fármacos , Factores de Edad , Animales , Peso Corporal/efectos de los fármacos , Peso Corporal/fisiología , Cronoterapia/métodos , Inyecciones Intraperitoneales , Masculino , Obesidad/tratamiento farmacológico , Obesidad/fisiopatología , Ratas , Ratas Sprague-Dawley , Ratas Zucker , Vigabatrin/fisiología , Pérdida de Peso/fisiología
8.
Drug Alcohol Depend ; 97(3): 216-25, 2008 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-18063319

RESUMEN

Relapse to drug use is a core feature of addiction. Previous studies demonstrate that gamma-vinyl GABA (GVG), an irreversible GABA transaminase inhibitor, attenuates the acute rewarding effects of cocaine and other addictive drugs. We here report that systemic administration of GVG (25-300 mg/kg) dose-dependently inhibits cocaine- or sucrose-induced reinstatement of reward-seeking behavior in rats. In vivo microdialysis data indicated that the same doses of GVG dose-dependently elevate extracellular GABA levels in the nucleus accumbens (NAc). However, GVG, when administered systemically or locally into the NAc, failed to inhibit either basal or cocaine-priming enhanced NAc dopamine in either naïve rats or cocaine extinction rats. These data suggest that: (1) GVG significantly inhibits cocaine- or sucrose-triggered reinstatement of reward-seeking behavior; and (2) a GABAergic-, but not dopaminergic-, dependent mechanism may underlie the antagonism by GVG of cocaine-triggered reinstatement of drug-seeking behavior, at least with respect to GVG's action on the NAc.


Asunto(s)
Conducta Adictiva/prevención & control , Conducta Animal/efectos de los fármacos , Cocaína/administración & dosificación , Dopamina/metabolismo , Conducta Exploratoria/efectos de los fármacos , Extinción Psicológica/efectos de los fármacos , GABAérgicos/farmacología , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Vigabatrin/farmacología , Animales , Cromatografía Líquida de Alta Presión , GABAérgicos/administración & dosificación , Masculino , Ratas , Ratas Long-Evans , Recompensa , Autoadministración , Vigabatrin/administración & dosificación
10.
Arch Ophthalmol ; 124(9): 1257-62, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16966620

RESUMEN

OBJECTIVE: To evaluate the ocular safety of short-term use of vigabatrin to treat cocaine and/or methamphetamine addiction. METHODS: Individuals who were actively using cocaine and/or methamphetamine were eligible for enrollment. Enrolled subjects were scheduled for comprehensive eye examinations at the beginning and end of the study. Visual field testing was performed at baseline and 1 week, 4 weeks, 8 weeks, and 1 month or more after discontinuing vigabatrin. Twenty-eight subjects received at least 1 dose of vigabatrin; however, only 20 subjects continued beyond the initial escalating vigabatrin dose phase to the treatment phase. Of these 20 subjects, 18 completed the study with full follow-up. Visual fields were evaluated subjectively by 2 glaucoma specialists and analyzed objectively for group and individual changes in quadrant mean sensitivity. The objective analysis was also repeated for superior field quadrants after excluding the uppermost peripheral points to minimize the eyelid effect. The main outcome measures were change of visual field, visual acuity, and ocular adverse effects. RESULTS: Vigabatrin seemed to help treat cocaine and/or methamphetamine addiction. Of 18 subjects, 16 had negative test results for cocaine and methamphetamine use during the last 6 weeks of the trial. No ocular adverse events were detected. The subjective evaluation did not reveal visual field constriction in any of the 18 evaluable participants. Objective group and individual analyses for quadrant mean sensitivity did not show any change from baseline in any quadrant. No changes in visual acuity were noted. CONCLUSIONS: In this short-term pilot study, vigabatrin seemed to help treat cocaine and/or methamphetamine abuse. There was no evidence of ocular or visual field adverse effects.


Asunto(s)
Trastornos Relacionados con Anfetaminas/tratamiento farmacológico , Trastornos Relacionados con Cocaína/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , GABAérgicos/uso terapéutico , Vigabatrin/uso terapéutico , Adulto , Trastornos Relacionados con Anfetaminas/fisiopatología , Trastornos Relacionados con Cocaína/fisiopatología , Inhibidores Enzimáticos/efectos adversos , Femenino , GABAérgicos/efectos adversos , Humanos , Masculino , Proyectos Piloto , Resultado del Tratamiento , Vigabatrin/efectos adversos , Pruebas del Campo Visual , Campos Visuales/efectos de los fármacos , Campos Visuales/fisiología
11.
Psychopharmacology (Berl) ; 186(2): 159-67, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16703400

RESUMEN

RATIONALE: Children and adolescents will readily abuse household products that contain solvents such as toluene. It is likely that reinforcing exposures to toluene alter brain glucose metabolism. OBJECTIVE: Using an animal model of drug reinforcement, we sought to identify a metabolic signature of toluene abuse in the adolescent rodent brain. Small animal PET (microPET), in combination with the glucose analog radiotracer, (18)FDG, were used to evaluate the metabolic consequences of inhaled toluene. METHODS: The exposure protocol paralleled our previously established method for assessing the conditioned reinforcing effects of toluene (5,000 ppm) using the conditioned place preference (CPP) paradigm. Animals were scanned at baseline and 2 h after the last exposure. Follow-up (18)FDG scans occurred 1 day, 3 weeks, and 2 months later. RESULTS: After six pairings, 38% of the animals preferred the toluene paired chamber and 25% were averse. The immediate metabolic effect in toluene-exposed animals was a 20% decline in whole brain (18)FDG uptake. Twenty-four hours following the last exposure, the whole brain decline was 40%, and 2 months later, the decline was 30% of pretoluene levels. A region-by-region analysis demonstrated significant additional decreases in the pons, cerebellum, striatum, midbrain, temporal cortex, and hippocampus. Two months after toluene cessation, regions of complete metabolic recovery were the thalamus and cerebellum; however, the temporal cortex did not recover. CONCLUSIONS: Brain uptake of (18)FDG appears to be a useful tool for examining the metabolic impact of toluene abuse, which include a profound decline followed by region-specific recovery after cessation.


Asunto(s)
Encéfalo/metabolismo , Exposición por Inhalación/efectos adversos , Solventes/toxicidad , Trastornos Relacionados con Sustancias/metabolismo , Tolueno/toxicidad , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Mapeo Encefálico , Modelos Animales de Enfermedad , Fluorodesoxiglucosa F18 , Masculino , Ratas , Ratas Sprague-Dawley , Refuerzo en Psicología , Trastornos Relacionados con Sustancias/diagnóstico por imagen , Trastornos Relacionados con Sustancias/etiología , Trastornos Relacionados con Sustancias/psicología , Tomografía Computarizada de Emisión
12.
Drug Discov Today ; 10(8): 547-62, 2005 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-15837598

RESUMEN

Neurochemical imaging studies can identify molecular targets of abused drugs and link them to the underlying pathology associated with behaviors such as drug dependence, addiction and withdrawal. positron emission tomography (PET) is opening new avenues for the investigation of the neurochemical disturbances underlying drug abuse and addiction and the in vivo mechanisms by which medications might ameliorate these conditions. PET can identify vulnerable human populations, treatment strategies and monitor treatment efficacy. Thus, with this tool and the knowledge it provides, the potential for developing novel drugs and treatment strategies for drug addiction is now close at hand.


Asunto(s)
Tomografía de Emisión de Positrones/estadística & datos numéricos , Trastornos Relacionados con Sustancias/diagnóstico , Animales , Predicción , Humanos , Tomografía de Emisión de Positrones/instrumentación , Tomografía de Emisión de Positrones/tendencias , Terminología como Asunto
13.
Synapse ; 55(2): 122-5, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15543630

RESUMEN

This study examined the safety and efficacy of gamma vinyl-GABA (GVG, vigabatrin) for the treatment of methamphetamine and/or cocaine addiction. A total of 30 subjects, who met DSM-IV criteria for methamphetamine and/or cocaine dependence, were enrolled in an open label 9-week safety study. The protocol was specifically designed to include extensive visual field monitoring as well as outcome measures of therapeutic efficacy. Patients were screened twice weekly for the presence of urinary cocaine, methamphetamine, heroin, alcohol, and marijuana. In total, 18/30 subjects completed the study and 16/18 tested negative for methamphetamine and cocaine during the last 6 weeks of the trial. GVG did not produce any visual field defects or alterations in visual acuity. Furthermore, it did not produce changes in vital signs even with continued use of methamphetamine and cocaine. Thus, under conditions that appear to be appropriate for the successful treatment of methamphetamine and/or cocaine addiction, GVG is safe.


Asunto(s)
Trastornos Relacionados con Cocaína/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , Metanfetamina , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Vigabatrin/uso terapéutico , Inhibidores Enzimáticos/efectos adversos , Femenino , Humanos , Masculino , Resultado del Tratamiento , Vigabatrin/efectos adversos
16.
Synapse ; 46(4): 240-50, 2002 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-12373739

RESUMEN

We examined the effect of (+/-)-gamma-vinyl GABA (GVG, Vigabatrin), an irreversible inhibitor of the enzyme GABA transaminase, on the acquisition and expression of cocaine-induced sensitization in albino male Sprague-Dawley rats. Animals received a single injection of 1 ml/kg i.p. of 0.9% saline or 15 mg/kg i.p. of (-)-cocaine and locomotor activity was assessed using automated locomotor cages and stereotyped behaviors were scored using a 4-point rating scale (Day 1). Subsequently, animals were given 15 mg/kg i.p. of cocaine every 48 h in their home cage for 1 week (Days 3, 5, and 7) and then given no treatment for 1 week. A challenge injection of 15 mg/kg i.p. of cocaine, but not vehicle, produced a significant increase in locomotor activity and stereotyped behaviors on Day 15 compared to animals that received cocaine on Day 1. Administration of 75 mg/kg i.p. of GVG 2.5 h before the cocaine injections did not significantly alter the acquisition of cocaine-induced locomotor sensitization. However, 150 mg/kg i.p. of GVG significantly attenuated the acquisition of cocaine-induced locomotor sensitization. Administration of 150 mg/kg i.p. of GVG 2.5 h before the cocaine challenge injection on Day 15 significantly attenuated the expression of cocaine-induced locomotor sensitization. Acquisition and expression of cocaine-induced sensitization of stereotypy was also significantly attenuated by 150 mg/kg i.p. of GVG. Since sensitization may be one of the factors involved in relapse to drug use, the present results, in combination with previous findings that GVG blocks the rewarding and incentive motivating effects of cocaine, suggest that GVG might prove useful in the treatment of cocaine addiction.


Asunto(s)
4-Aminobutirato Transaminasa/antagonistas & inhibidores , Cocaína/farmacología , Actividad Motora/efectos de los fármacos , Conducta Estereotipada/efectos de los fármacos , Vigabatrin/farmacología , 4-Aminobutirato Transaminasa/metabolismo , Animales , Conducta Adictiva/tratamiento farmacológico , Conducta Adictiva/enzimología , Masculino , Actividad Motora/fisiología , Ratas , Ratas Sprague-Dawley , Conducta Estereotipada/fisiología , Vigabatrin/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA